MC
KALV

Menta Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Menta Capital’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,739
Closed -$139K – 967
2015
Q4 		$139K Buy
2,739
+437
+19% +$22.9K 0.02% 805
2015
Q3 		$115K Buy
+2,302
New +$196K 0.02% 672

Other funds holding KALV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Menta Capital's KALV Position: Q1 2016 in Review

Menta Capital sold out of KalVista Pharmaceuticals (KALV) in Q1 2016, closing a stake of 2,739 shares — an estimated $139K sold.

Menta Capital first reported a position in KALV in Q3 2015 and held it in 2 quarters. The position peaked at $139K in Q4 2015. 32 funds tracked by Wall St. Rank hold KALV as of Q1 2016.

  • Menta Capital reported no remaining KalVista Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Menta Capital sold 2,739 KalVista Pharmaceuticals shares in Q1 2016, an estimated $139K.
  • Menta Capital first reported a position in KalVista Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Menta Capital's KalVista Pharmaceuticals position peaked at $139K in Q4 2015.
  • 32 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2016.

Based on Menta Capital's 13F filing for Q1 2016, filed 11 May 2016.